C4 Therapeutics, Inc. — Director's Dealing 2020

Oct 2, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2020-10-01

Reporting Person: Crystal Adam (Chief Medical Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$6.50	2029-04-08	Common Stock (172292)		Direct
Stock Option (Right to Buy)	$4.98	2030-07-02	Common Stock (198108)		Direct
Stock Option (Right to Buy)	$4.98	2030-07-08	Common Stock (74080)		Direct

Footnotes

F1: 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter.

F2: This option shall vest and become exercisable in 20 equal quarterly installments, with the first installment vesting on September 5, 2020.